PMGC Holdings (ELAB) Share-based Compensation (2022 - 2026)
PMGC Holdings (ELAB) posted Share-based Compensation of $8216.0 for Q1 2026, down 22.91% sequentially from $10657.0 in Q4 2025, and up 113.96% YoY from $3839.9 in Q1 2025.
PMGC Holdings (ELAB) Share-based Compensation (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Share-based Compensation for 5 years, with the latest figure at $8216.0 in Q1 2026.
- Quarterly Share-based Compensation rose 113.96% year-over-year to $8216.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47895.0 (up 381.59% YoY) and the FY2025 annual result came in at -$19160.0, down 119.72% from the prior year.
- Share-based Compensation retreated to $8216.0 in Q1 2026 per ELAB's latest filing, from $10657.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $35.6 million in Q3 2022 and troughed at -$93.9 million in Q4 2022.
- A 5-year average of -$3.9 million and a median of $39646.0 in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 135.32% in 2025, down 206.32% in 2025.
- Over 5 years, Share-based Compensation stood at -$93.9 million in 2022, then jumped by 100.15% to $141190.0 in 2023, then plunged by 71.92% to $39646.0 in 2024, then slumped by 73.12% to $10657.0 in 2025, then decreased by 22.91% to $8216.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $8216.0, $10657.0, and $13180.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | 174,545.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,216.00 |
| Mar 31, 2026 | 8,216.00 |
| Dec 31, 2025 | 10,657.00 |
| Dec 31, 2025 | 10,657.00 |
| Sep 30, 2025 | 13,180.00 |
| Sep 30, 2025 | 13,180.00 |
| Jun 30, 2025 | 15,842.00 |
| Jun 30, 2025 | 15,842.00 |
| Mar 31, 2025 | -58,838.00 |
| Mar 31, 2025 | -58,838.00 |
| Dec 31, 2024 | 39,646.00 |
| Dec 31, 2024 | 39,646.00 |
| Sep 30, 2024 | 47,038.00 |
| Sep 30, 2024 | 47,038.00 |
| Jun 30, 2024 | -44,855.00 |
| Jun 30, 2024 | -44,855.00 |
| Mar 31, 2024 | 55,339.00 |
| Mar 31, 2024 | 55,339.00 |
| Dec 31, 2023 | 141,190.00 |
| Dec 31, 2023 | 141,190.00 |